Checkpoint Therapeutics, Inc. (CKPT)

Market Cap	183.12M
Revenue (ttm)	47,000
Net Income (ttm)	-46.47M
Shares Out	48.83M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,195,628
Open	3.350
Previous Close	3.370
Day's Range	3.330 - 3.760
52-Week Range	1.380 - 4.500
Beta	1.31
Analysts	Strong Buy
Price Target	10.33 (+175.47%)
Earnings Date	Nov 12, 2024

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CKPT
• Website: https://checkpointtx.com

Financial Performance

In 2023, Checkpoint Therapeutics's revenue was $103,000, a decrease of -46.35% compared to the previous year's $192,000. Losses were -$51.85 million, -17.21% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 175.47% from the latest price.

Price Target

$10.33

(175.47% upside)

Analyst Consensus: Strong Buy